SAIC Awarded Contract by National Institute of Allergy and Infectious Diseases
Company to Provide Preclinical Services for the Development of Biopharmaceutical Products for Infectious Diseases
MCLEAN, Va., Oct. 19, 2011 /PRNewswire/ -- Science Applications International Corporation (SAIC) (NYSE: SAI) announced today it was awarded a contract by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), to provide preclinical services for the development of biopharmaceutical products for infectious diseases. The contract was funded $1.9 million at the end of fiscal year 2011. The total funding could be up to $102 million over the ten year period of performance, subject to availability of annual appropriations.
Research supported by NIAID, NIH, and the Department of Health and Human Services strives to understand, treat and ultimately prevent a myriad of infectious, immunologic and allergic diseases that threaten millions of human lives. Under the contract, SAIC will provide a suite of biopharmaceutical product development services, either directly or through management of subcontractors in areas including: feasibility assessments, assay development, process development, cGMP manufacture, and regulatory activities.
"SAIC is pleased to assist and support NIAID with the development of biopharmaceutical products that will help prevent harmful diseases and improve human health," said Steve Comber, SAIC senior vice president and business unit general manager.
About SAIC
SAIC is a FORTUNE 500® scientific, engineering, and technology applications company that uses its deep domain knowledge to solve problems of vital importance to the nation and the world, in national security, energy & environment, health and cybersecurity. The company's approximately 41,000 employees serve customers in the U.S. Department of Defense, the intelligence community, the U.S. Department of Homeland Security, other U.S. Government civil agencies and selected commercial markets. Headquartered in McLean, Va., SAIC had annual revenues of approximately $11 billion for its fiscal year ended January 31, 2011. For more information, visit saic.com. SAIC: From Science to Solutions®
Statements in this announcement, other than historical data and information, constitute forward-looking statements that involve risks and uncertainties. A number of factors could cause our actual results, performance, achievements, or industry results to be very different from the results, performance, or achievements expressed or implied by such forward-looking statements. Some of these factors include, but are not limited to, the risk factors set forth in SAIC's Annual Report on Form 10-K for the period ended January 31, 2011, and other such filings that SAIC makes with the SEC from time to time. Due to such uncertainties and risks, readers are cautioned not to place undue reliance on such forward-looking statements, which speak only as of the date hereof.
Contact: |
Melissa Koskovich |
Vernon Guidry |
|
(703) 676-6762 |
(703) 676-6533 |
|
||
|
|
|
SOURCE SAIC
WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?
Newsrooms &
Influencers
Digital Media
Outlets
Journalists
Opted In
Share this article